Clinical trial
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In…
NCT00338247 · Novartis, Industry · Approved for marketing
Key facts
| NCT number | NCT00338247 |
|---|---|
| Title | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer |
| Official title | An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Novartis, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib + capecitabine |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2015 |
| Completion | Mar 1, 2015 |
| First posted | Jun 20, 2006 |
| Last update posted | Apr 6, 2016 |
| Countries | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Cyprus, Czechia, Denmark, Estonia and 33 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: